3 ways Rebif was proven effective
Rebif® (interferon beta-1a) is proven to meet 3 key treatment goals in relapsing MS.
|Slowed disability progression||Reduced relapse rate||Reduced active brain lesions on studied MRI measures*†|
|Slowed disability progression||Yes|
|Reduced relapse rate||Yes|
|Reduced active brain lesions on studied MRI measures*†||Yes|
This was shown in a large placebo-controlled study of Rebif for relapsing MS called PRISMS.‡ "Placebo-controlled" means that some people in the study received a placebo containing no medicine, while others received Rebif. This is a very common way to study the effectiveness of drugs.
The study included a range of disability in relapsing MS based on their Expanded Disability Status Scale (EDSS) scores. EDSS is used in clinical studies to rate the amount of disability a person has over time on a scale from 0 (least) to 10 (maximum). People in the PRISMS study ranged from 0 to 5.0 on the scale.
The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.
‡Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis.
Study results showed Rebif was effective for people with relapsing MS with a range of disability.
The PRISMS study also showed only 26% of people taking Rebif 44 mcg had disability progression§—as opposed to 37% of those taking a placebo. The time to progression of disability, which is the permanent worsening of your neurologic examination over time, was also nearly doubled versus placebo (21.3 months vs 11.9 months).
In the PRISMS study, 3% of those taking Rebif 22 mcg and 5% taking Rebif 44 mcg stopped taking Rebif because of adverse events.
It's important to inform your healthcare provider of any side effects you experience. There may be things you can do to help manage them.
Please see Important Safety Information below and the Rebif Medication Guide and Prescribing Information at the top of this website, and speak with your healthcare provider for more information.
New or enlarging lesions detected with PD/T2-weighted MRI.
† Refers to new lesions and total lesion burden or area as defined in the AAN and MS Council guidelines.
§ Progression of disability was defined as an increase of at least 1 point in the EDSS that was sustained for at least 3 months.
" The central or typical value in a set of data.
¶ From a subgroup of 134 patients in the PRISMS study who received 11 consecutive monthly PD/T2 and gadolinium-enhanced/T1-weighted (Gd-T1) MRI scans beginning 1 month before treatment initiation.
# A value in an ordered set that has an equal number of values higher and lower.
** Based on comparisons from rank-based ANOVA.
Looking at the options
"I needed to feel
and I could
something to treat
my relapsing MS."
My diagnosis was difficult on my entire family, especially my children. I knew our lives would be different, but I told them I was going to work with my neurologist to learn how we could treat my relapsing MS.
So the doctor and I talked about treatment options, and she thought Rebif was a good choice for me. She explained the risks, side effects, and benefits of Rebif and said that some evidence from clinical trials has shown that Rebif helps reduce the frequency of relapses and could help slow disability progression associated with relapsing multiple sclerosis.
She also told me that Rebif had been shown to reduce the development of certain brain lesions that you can see on MRIs. What that might mean about my symptoms or how much disability I might have in the future can't be predicted. But my MRI results showed that I had multiple lesions on my brain at the time, so it really got my attention.
And though I realized that there is no cure for MS, I felt ready to start treatment. I needed to feel like my doctor and I could do something to treat my relapsing MS. We talked it over and that is how I decided on Rebif.
Nicole B. Avid fisher and mom, MS LifeLines Ambassador, living with relapsing MS
This story reflects the personal experience of one person. Results and experiences vary from patient to patient.